Skip to content

Study of Proteins in Head and Neck Cancer Cells

Novel Protein Regulator of Tumor Suppressor ARF & NF-κB

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00896948
Enrollment
Unknown
Registered
2009-05-12
Start date
2005-05-31
Completion date
Unknown
Last updated
2017-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

head and neck cancer

Brief summary

RATIONALE: Studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at proteins in head and neck cancer cells.

Detailed description

OBJECTIVES: * Define the function and mechanism of LZAP in regulating ARF. * Determine the mechanism and biological consequences of LZAP inhibition of NF-κB. * Determine if LZAP has tumor suppressor activity by conditional targeting of LZAP in mice. OUTLINE: Using molecular laboratory techniques, this study examines the biochemical mechanisms by which LZAP activates transcriptional, tumor suppressive activity (both p53-dependent and p53-independent) of ARF and inhibits transcriptional, tumorigenic activity of NF-kB. LZAP regulation of newly identified ARF activities, such as S-phase delay and ARF-mediated B23 degradation are also evaluated. LZAP's tumor suppressive activity is assessed in vivo using a conditional knockout vector to target LZAP in mice and to observe for spontaneous and induced tumor formation. Laboratory analyses used to determine study endpoints include standard recombinant DNA, recombinant protein expression and purification, cell culture and transfection, cell labeling, reporter assays, flow cytometry, yeast-two hybrid, immunoprecipitation, immunoblotting, immunofluorescence, TUNEL assay, ELISA assay, Southern blotting, and protein and gene expression.

Interventions

GENETICgene expression analysis
GENETICprotein expression analysis
OTHERflow cytometry
OTHERimmunoenzyme technique
OTHERimmunohistochemistry staining method
OTHERimmunologic technique

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Vanderbilt University Medical Center
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 120 Years
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Head and neck cancer tumor cell line PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

MeasureTime frame
Function and mechanism of LZAP in regulating ARF
Mechanism and biological consequences of LZAP inhibition of NF-κB
Determination of LZAP tumor suppressor activity

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026